Publication No Sample Clauses

Publication No. Patent No. [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****] [****]
AutoNDA by SimpleDocs
Publication No. Patent No. Status [***]
Publication No. Title Filing Date Patent No. Issue Date Expiration Date Status China CN 124418-32078 PAZ-320-1 CNDV DIV 201510265009.X 104844472B SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/26/2009 ZL201510265009.X 02/13/2018 05/26/2029 Granted Xxxxx XX 000000-00000 PAZ-320-1 MODV DIV J/003079 SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/26/2009 J/003079 08/07/2018 05/26/2029 Granted Hong Kong HK 124418-32039 PAZ-320-1-HK EP 11109171.9 1154757 SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/26/2009 HK1154757 12/18/2015 05/26/2029 Granted Hong Kong HK 124418-32038 PAZ-320-1HKDV DIV 15105134.9 1204526A SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/26/2009 Pending Taiwan TW 124418-32063 PAZ-320-1-TW ORD 098117308 SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/25/2009 I585071 06/01/2017 05/25/2029 Granted Taiwan TW 124418-32088 PAZ-320-1 TWDV DIV 106103523 201741281 SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/25/2009 I680117 12/21/2019 05/25/2029 Granted Taiwan TW 124418-32018 PAZ-320-1 TWDV2 DIV 108126026 SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 05/25/2009 Pending China CN 124418-51128 PAZ-511CN PCT 201780032098.0 109152789 METHODS FOR TREATING AND PREVENTING C. DIFFICILE INFECTION 03/24/2017 Pending ACTIVE/105323943.11
Publication No. 69 SCHEDULE C-1 NIKON DISCLOSURES PURSUANT TO SECTION 6.3.2(a) All Patents that are based on the same priority document as the Patents listed in the following table shall be deemed part of Schedule C-1 without being expressly listed in the following table. Country Application Date of Laid open Date Laid Patent Name number filing number Open number Counterpart Patents ----- ----------- ------- --------- --------- ------ ------------------- *** 70 SCHEDULE C-2 NIKON DISCLOSURES PURSUANT TO SECTION 6.3.2(b) *** SCHEDULE D SCHEDULE D PATENTS The three Patent applications having international publication numbers: *** *** *** 72 SCHEDULE E DESIGNATED NIKON PATENTS The three Patent applications having international publication numbers: *** *** *** SCHEDULE F SPECIFIED ENTITY ***, a corporation organized under the laws of ***.
Publication No. Title Filing Date Patent No. Issue Date Expiration Date Status Hong Kong HK 124418-51139 PAZ-511HK PCT 19127080.0 40003650A METHODS FOR TREATING AND PREVENTING C. DIFFICILE INFECTION 03/24/2017 Pending China CN 124418-51528 PAZ-515CN PCT 201780058535.6 109789153 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF 08/03/2017 Pending Hong Kong HK 124418-51539 PAZ-515HK PCT 19133244.4 40009772 A 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF 08/03/2017 Pending Taiwan TW 124418-51563 PAZ-515TW ORD 106126049 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF 08/02/2017 Pending China CN 124418-51728 PAZ-517CN PCT 201780079110.3 110087655 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USE THEREOF IN TREATING COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) 10/31/2017 Pending ACTIVE/105323943.11
Publication No. Title Filing Date Patent No. Issue Date Expiration Date Status Hong Kong HK 124418-51739 PAZ-517HK PCT 62020003975.3 40014127 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USE THEREOF IN TREATING COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) 10/31/2017 Pending Taiwan TW 124418-51763 PAZ-517TW ORD 106137764 201821082 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USE THEREOF IN TREATING COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP) 11/01/2017 Pending ACTIVE/105323943.11 Trademarks in the Territory Trademark Country App. No. NUZYRA CN 31636176 (Class 5) CN 35827956 (Class 35) HK 304951639 (Class 5) MO N/155342 (Class 5) TW 107063000 (Class 5) (Class 5) CN 31636177 CN 38800002 (Class 35) CN 38783109 (Class 44) CN 31636177A (Class 5 & 44) TW 107038311 NUZYRA CENTRAL CN 37002978 (Class 5) 37002977 (Class 16) 37002976 (Class 36) 37002975 (Class 39) 37002974 (Class 44) 238584769 v5
Publication No. Patent No. Country Application No. Publication No. Patent No. Country Application No. Publication No. Patent No. Country Application No. Publication No. Patent No. Country Application No. Publication No. Patent No. EXHIBIT C Development Plan [****] EXHIBIT D Third Party Licenses [****] EXHIBIT E
AutoNDA by SimpleDocs
Publication No. Patent No. [***] [***] [***] [***] Exhibit B MacroGenics Licensed Trademarks [***] Exhibit C Global Development Plan and Territory Specific Development Plan [***] Exhibit D SAFETY MANAGEMENT PLAN COMPONENTS [***] Exhibit E Product Royalty Rates Applicable Product Aggregate Net Sales threshold of the applicable Products in the Territory: Then the Product Royalty Rate Percentage shall be (%): Margetuximab Products On that portion of aggregate Net Sales in a Calendar Year less than [***] [***] On the portion of Net Sales in a Calendar Year equal to or greater than [***] but less than [***] [***] On that portion of Net Sales in a Calendar Year greater than [***] 20 MGD013 Products All [***] [***] Trident Products All [***] [***]
Publication No. 2132571 Patent Cooperation Treaty Sensitive Immunochromatographic Assay Application Date: April 10, 2003 Publication Date: October 23, 2003 Application No.: PCT/CA03/00539 Publication No.: WO03/087822 Modular Assay Reader System And Apparatus Application Date: March 19, 2008 Publication Date: October 9, 2008 Application No.: PCT/US2008/003609 Publication No.: WO2008/121239 Heated Assays For Influenza Application Date: January 6, 2009 Publication Date: July 23, 2009 Application No.: PCT/US2009/000035 Publication No.: WO2009/091501 Australia Multiple Analyte Immunoassay Application Date: December 11, 2007 Application No.: 2007332776 Canada Multiple Analyte Immunoassay Application Date: December 11, 2007 Application No.: 2671578 Comparative Multiple Analyte Assay Application Date: February 15, 2008 Application No.: 2677977 China (People's Republic) Sensitive Immunochromatographic Assay Application Date: April 10, 2003 Publication Date: July 27, 2005 Application No.: 3808096.6 Publication No.: CN1646913 Multiple Analyte Immunoassay Application Date: December 11, 2007 Application No.: 200780049910.7 India Multiple Analyte Immunoassay Application Date: December 11, 2007 Application No.: 3613DELNP2009 Hong Kong Sensitive Immunochromatographic Assay Application Date: January 3, 2006 Publication Date: April 21, 2006 Application No.: 61000235 Publication No.: 1080142A Mexico Multiple Analyte Immunoassay Application Date: December 11, 2007 Application No.: MXA2009006205 United States of America Immunoassay Employing Two-Step Internal Calibration Reaction Application Date: December 21, 2009 Publication Date: May 27, 2010 Application No.: 12/643,039 Publication No.: 20100129936 Multiple Analyte Immunoassay Application Date: June 4, 2009 Publication Date: February 25, 2010 Application No.: 12/478,305 Publication No.: 20100047857 Heated Assays For Influenza Application Date: July 12, 2010 Application No.: 12/834,116 TRADEMARKS Xxxx Registration Date Registration No. United States of America R LOGO August 6, 2002 2605067 RAMP EXPANDED October 8, 2002 2632327 RAMP RESPONSE BIOMEDICAL & DESIGN October 21, 2008 3521400 Canada R LOGO September 3, 2002 566825 RAMP September 3, 2002 566826 RAMP RESPONSE BIOMEDICAL & DESIGN February 24, 2010 TMA760,109 European Community R LOGO August 19, 1998 913947 RAMP February 20, 1997 474247 RAMP RESPONSE BIOMEDICAL & DESIGN July 24, 2008 6133797 Japan RAMP December 28, 2007 5101824 RAMP RESPONSE BIOMEDICAL & DESIGN November 22, 2007 509406...

Related to Publication No

  • Publication No copies of sketches, schedules, written documents, computer based data, photographs, maps or graphs, including graphic art Work, resulting from performance or prepared in connection with this Contract, are to be released by Contractor and/or anyone acting under the supervision of Contractor to any person, partnership, company, corporation, or agency, without prior written approval by the County, except as necessary for the performance of the services of this Contract. All press contacts, including graphic display information to be published in newspapers, magazines, etc., are to be administered only after County approval.

  • zone Information Publication ICANN’s publication of root-zone contact information for the TLD will include Registry Operator and its administrative and technical contacts. Any request to modify the contact information for the Registry Operator must be made in the format specified from time to time by ICANN at xxxx://xxx.xxxx.xxx/domains/root/.

  • Root-­‐zone Information Publication ICANN’s publication of root-­‐zone contact information for the TLD will include Registry Operator and its administrative and technical contacts. Any request to modify the contact information for the Registry Operator must be made in the format specified from time to time by ICANN at xxxx://xxx.xxxx.xxx/domains/root/.

  • Directory Publication Nothing in this Agreement shall require Verizon to publish a directory where it would not otherwise do so.

  • Non-Publication The parties mutually agree not to disclose publicly the terms of this Agreement except to the extent that disclosure is mandated by applicable law or regulation or to their respective advisors (e.g., attorneys, accountants).

  • Publications All published material and written reports submitted under the Contract must be originally developed material unless otherwise specifically provided in the Contract. When material not originally developed is included in a report in any form, the source shall be identified.

  • Scientific Publications During the Research Program Term, neither Party shall first publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by the other Party. Each Party agrees to provide the other Party with the opportunity to review any proposed abstract, manuscript or scientific presentation (including any verbal presentation) that relates to its activities performed pursuant to this Agreement during the Research Program Term, at least [**] days prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time up to [**] to secure patent protection for any material in such publication that it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications first with respect to activities performed or results obtained pursuant to this Agreement during the Research Program Term, or not to publish at all if necessary to preserve trade secrets. The Parties agree to review and decide whether to delay publication of such information to permit filing of patent applications. Neither Party shall have the right to publish or present any Confidential Information of the other Party, except as provided in Section 9.2. After the Research Program Term, each Party and its Affiliates may publish or present results, data or scientific findings of any of their activities without the prior review of the other Party, provided that such publication or presentation does not disclose any of the other Party’s Confidential Information. Nothing contained in this Section 9.3 shall prohibit the inclusion of information necessary for a patent application; provided that the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application in accordance with Section 8.2. Nothing contained in this Section 9.3 shall prohibit either Party from disclosing the results, data or scientific findings of any activity performed by the other Party or its Affiliates pursuant to this Agreement without prior review and prior written consent of the other Party, where required, as reasonably determined by the disclosing Party’s legal counsel, by applicable law; provided that if a Party is required by law to make any such disclosure, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise).

  • PUBLICATION OF AGREEMENT The Department will publish an abridged version of this Agreement on the WA health system internet site, in accordance with Schedule D9 of the NHRA. Any subsequent amendments to this Agreement will also be published in accordance with Schedule D9 of the NHRA.

  • Petition for Annual Conference Session The Local Church acknowledges that pursuant to the governing standing rules of the Annual Conference, petitions for consideration of the legislative body must be submitted to the Secretary of the Annual Conference on or before April 1 of the current Annual Conference year. The Annual Conference will make reasonable efforts to assist the Local Church in completing the required petition, which will include this Disaffiliation Agreement as an attachment thereto making it subject to public review. If the petition is not filed in a timely manner, the Parties will make good faith efforts under the standing rules of the Annual Conference to cooperate to bring the petition to the legislative floor for consideration by appropriate motions to suspend the standing rules for the purposes of considering the petition.

  • Public Disclosures The Company shall not, nor shall it permit any Subsidiary to, disclose any Investor’s name or identity as an investor in the Company in any press release or other public announcement or in any document or material filed with any governmental entity (other than tax filings in the ordinary course), without the prior written consent of such Investor, unless such disclosure is required by applicable law or governmental regulations or by order of a court of competent jurisdiction, in which case prior to making such disclosure the Company shall give written notice to such Investor describing in reasonable detail the proposed content of such disclosure and shall permit such Investor to review and comment upon the form and substance of such disclosure.

Time is Money Join Law Insider Premium to draft better contracts faster.